CVE:BTI

Bioasis Technologies Competitors

C$0.34
-0.05 (-11.69 %)
(As of 04/16/2021 10:44 AM ET)
Add
Compare
Today's Range
C$0.29
Now: C$0.34
C$0.35
50-Day Range
C$0.35
MA: C$0.39
C$0.44
52-Week Range
C$0.15
Now: C$0.34
C$0.70
Volume258,467 shs
Average Volume75,686 shs
Market CapitalizationC$24.43 million
P/E Ratio30.91
Dividend YieldN/A
BetaN/A

Competitors

Bioasis Technologies (CVE:BTI) Vs. COV, EMH, IGX, QPT, CZO, and CTX

Should you be buying BTI stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Bioasis Technologies, including Covalon Technologies (COV), Emerald Health Therapeutics (EMH), IntelGenx Technologies (IGX), Quest PharmaTech (QPT), Ceapro (CZO), and Crescita Therapeutics (CTX).

Covalon Technologies (CVE:COV) and Bioasis Technologies (CVE:BTI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Valuation & Earnings

This table compares Covalon Technologies and Bioasis Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Covalon TechnologiesC$23.84 million1.43C$-6,144,922.00C($0.24)-5.55
Bioasis TechnologiesC$4.12 million5.94C$790,284.00C$0.0130.91

Bioasis Technologies has lower revenue, but higher earnings than Covalon Technologies. Covalon Technologies is trading at a lower price-to-earnings ratio than Bioasis Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Covalon Technologies and Bioasis Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Covalon TechnologiesN/AN/AN/A
Bioasis TechnologiesN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Covalon Technologies and Bioasis Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Covalon Technologies0000N/A
Bioasis Technologies0000N/A

Summary

Bioasis Technologies beats Covalon Technologies on 4 of the 5 factors compared between the two stocks.

Emerald Health Therapeutics (CVE:EMH) and Bioasis Technologies (CVE:BTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, analyst recommendations, profitability, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Emerald Health Therapeutics and Bioasis Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emerald Health Therapeutics0000N/A
Bioasis Technologies0000N/A

Profitability

This table compares Emerald Health Therapeutics and Bioasis Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emerald Health TherapeuticsN/AN/AN/A
Bioasis TechnologiesN/AN/AN/A

Valuation and Earnings

This table compares Emerald Health Therapeutics and Bioasis Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emerald Health TherapeuticsC$13.02 million4.02C$-142,699,488.00C($0.70)-0.37
Bioasis TechnologiesC$4.12 million5.94C$790,284.00C$0.0130.91

Bioasis Technologies has lower revenue, but higher earnings than Emerald Health Therapeutics. Emerald Health Therapeutics is trading at a lower price-to-earnings ratio than Bioasis Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Bioasis Technologies beats Emerald Health Therapeutics on 4 of the 5 factors compared between the two stocks.

Bioasis Technologies (CVE:BTI) and IntelGenx Technologies (CVE:IGX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Valuation and Earnings

This table compares Bioasis Technologies and IntelGenx Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioasis TechnologiesC$4.12 million5.94C$790,284.00C$0.0130.91
IntelGenx TechnologiesC$1.54 million43.49C$-9,064,710.00C($0.08)-7.41

Bioasis Technologies has higher revenue and earnings than IntelGenx Technologies. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Bioasis Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Bioasis Technologies and IntelGenx Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bioasis Technologies0000N/A
IntelGenx Technologies0000N/A

Profitability

This table compares Bioasis Technologies and IntelGenx Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bioasis TechnologiesN/AN/AN/A
IntelGenx TechnologiesN/AN/AN/A

Summary

Bioasis Technologies beats IntelGenx Technologies on 4 of the 5 factors compared between the two stocks.

Bioasis Technologies (CVE:BTI) and Quest PharmaTech (CVE:QPT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings for Bioasis Technologies and Quest PharmaTech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bioasis Technologies0000N/A
Quest PharmaTech0000N/A

Profitability

This table compares Bioasis Technologies and Quest PharmaTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bioasis TechnologiesN/AN/AN/A
Quest PharmaTechN/AN/AN/A

Earnings and Valuation

This table compares Bioasis Technologies and Quest PharmaTech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioasis TechnologiesC$4.12 million5.94C$790,284.00C$0.0130.91
Quest PharmaTechC$38,871.00474.71C$109.88 millionC$0.660.17

Quest PharmaTech has lower revenue, but higher earnings than Bioasis Technologies. Quest PharmaTech is trading at a lower price-to-earnings ratio than Bioasis Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Quest PharmaTech beats Bioasis Technologies on 3 of the 5 factors compared between the two stocks.

Ceapro (CVE:CZO) and Bioasis Technologies (CVE:BTI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Profitability

This table compares Ceapro and Bioasis Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CeaproN/AN/AN/A
Bioasis TechnologiesN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for Ceapro and Bioasis Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ceapro0000N/A
Bioasis Technologies0000N/A

Earnings & Valuation

This table compares Ceapro and Bioasis Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CeaproC$16.14 million3.56C$2.56 millionC$0.0322.42
Bioasis TechnologiesC$4.12 million5.94C$790,284.00C$0.0130.91

Ceapro has higher revenue and earnings than Bioasis Technologies. Ceapro is trading at a lower price-to-earnings ratio than Bioasis Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Ceapro beats Bioasis Technologies on 3 of the 5 factors compared between the two stocks.

Crescita Therapeutics (TSE:CTX) and Bioasis Technologies (CVE:BTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Crescita Therapeutics and Bioasis Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Crescita TherapeuticsN/AN/AN/A
Bioasis TechnologiesN/AN/AN/A

Earnings & Valuation

This table compares Crescita Therapeutics and Bioasis Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crescita TherapeuticsC$15.64 million1.12C$41,296.00C$0.00425.00
Bioasis TechnologiesC$4.12 million5.94C$790,284.00C$0.0130.91

Bioasis Technologies has lower revenue, but higher earnings than Crescita Therapeutics. Bioasis Technologies is trading at a lower price-to-earnings ratio than Crescita Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Crescita Therapeutics and Bioasis Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Crescita Therapeutics0000N/A
Bioasis Technologies0000N/A

Summary

Bioasis Technologies beats Crescita Therapeutics on 3 of the 5 factors compared between the two stocks.


Bioasis Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
COV
Covalon Technologies
0.6$1.32-3.0%C$37.44 millionC$23.84 million-5.55News Coverage
Gap Up
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.26-5.9%C$34.02 millionC$13.02 million-0.37Gap Up
IGX
IntelGenx Technologies
0.9$0.60-5.0%C$30.87 millionC$1.54 million-7.41
QPT
Quest PharmaTech
0.8$0.11-13.6%C$21.76 millionC$38,871.000.17Gap Down
CZO
Ceapro
0.7$0.74-5.4%C$21.65 millionC$16.14 million22.42Gap Up
CTX
Crescita Therapeutics
0.6$0.85-1.2%C$17.55 millionC$15.64 million425.00
KNE
Kane Biotech
0.4$0.17-3.0%C$14.12 millionC$1.34 million-4.71Gap Down
GSD
Devonian Health Group
0.5$0.26-3.8%C$13.96 millionC$1.59 million-5.42Gap Up
PAS
Pascal Biosciences
0.6$0.09-11.8%C$12.70 millionN/A-3.86High Trading Volume
NSP
Naturally Splendid Enterprises
0.6$0.07-7.7%C$11.06 millionC$2.03 million-1.51
MPH
Medicure
0.7$1.61-1.9%C$10.80 millionC$12.71 million-1.04
HEM
Hemostemix
0.6$0.37-1.4%C$9.07 millionN/A-2.20
ICO
iCo Therapeutics
0.5$0.11-0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.40-7.6%C$6.94 millionC$5.60 million7.31Gap Down
IOT
Innovotech
0.8$0.16-6.3%C$6.52 millionC$1.04 million80.00
BCT
BriaCell Therapeutics
0.5$4.10-2.4%C$4.48 millionN/A-1.32
RVV
Revive Therapeutics
0.5$0.08-12.5%C$3.62 millionN/A-3.64High Trading Volume
News Coverage
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04-71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03-16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01-0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$46.18-0.0%C$0.00C$267.59 million50.75News Coverage
LTY
Liberty Biopharma
0.6$2.00-100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
SCYB
Scythian Biosciences
0.5$3.49-6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32-5.3%C$0.00N/A0.00Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.